Notice: This company has been marked as potentially delisted and may not be actively trading. Entasis Therapeutics (ETTX) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Hedge Fund and Insider Trading News: D.E. Shaw, Elliott Management, Millennium Management, Marshall Wace LLP, Three Arrows Capital, Entasis Therapeutics Holdings Inc. (ETTX), Gossamer Bio Inc (GOSS), and MoreJuly 18, 2022 | insidermonkey.comTrading was temporarily halted for "ETTX" at 07:07 PM with a stated reason of "News pending."July 11, 2022 | marketbeat.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | finance.yahoo.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates MANT, ETTX, CTEKJune 9, 2022 | apnews.comScott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTXJune 3, 2022 | apnews.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ETTX, CDEV, CTEKMay 31, 2022 | apnews.comShort Interest in Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Decreases By 35.4%Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX - Get Rating) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 105,100 shares, a decline of 35.4% from the April 30th total of 162,700 shares. Based on an average daily trading volume, of 169,900 shares, the short-interest ratio is presently 0.6 days. Currently, 0.7% of the company's shares are short sold.May 29, 2022 | marketbeat.comBiotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers UpdatesMay 25, 2022 | finance.yahoo.comENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the FirmMay 25, 2022 | apnews.comSHAREHOLDER ALERT: Halper Sadeh LLP Investigates ETTX, CTEK, VSAT, WLL, LHCGMay 24, 2022 | apnews.comAstraZeneca spinout, based in Waltham, acquired at 60% premiumMay 24, 2022 | finance.yahoo.comInvestor Alert - The M&A Class Action Firm Announces an Investigation of Entasis Therapeutics Holdings Inc. - ETTXMay 24, 2022 | benzinga.comETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to ShareholdersMay 23, 2022 | apnews.comTrading was temporarily halted for "ETTX" at 08:05 AM with a stated reason of "News pending."May 23, 2022 | marketbeat.comAntibiotic resistance efforts get a boost as CARB-X gets $370MMay 19, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual ConferenceMay 17, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual ConferenceMay 17, 2022 | finance.yahoo.comEntasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business UpdateApril 27, 2022 | finance.yahoo.comEntasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business UpdateApril 27, 2022 | finance.yahoo.comEntasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 ConferenceApril 26, 2022 | finance.yahoo.comEntasis Flat on DataApril 18, 2022 | baystreet.caEntasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 ConferenceApril 18, 2022 | finance.yahoo.comAlliance Global Partners Downgrades Entasis Therapeutics Hldg to NeutralMarch 16, 2022 | benzinga.comEntasis Therapeutics (NASDAQ:ETTX) Downgraded by Alliance Global Partners to NeutralAlliance Global Partners downgraded Entasis Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday.March 16, 2022 | marketbeat.comEntasis Shares Rise After Innoviva Raises Buyout Price to $2 a ShareMarch 15, 2022 | marketwatch.comEntasis Therapeutics (NASDAQ:ETTX) Rating Increased to Buy at Zacks Investment ResearchZacks Investment Research raised Entasis Therapeutics from a "hold" rating to a "buy" rating and set a $2.00 target price on the stock in a research report on Tuesday.March 8, 2022 | marketbeat.comWedbush Downgrades Entasis Therapeutics Hldg to Neutral, Lowers Price Target to $1.8March 8, 2022 | benzinga.comHC Wainwright & Co. Downgrades Entasis Therapeutics Hldg to Neutral, Lowers Price Target to $1.8March 4, 2022 | benzinga.comEntasis Therapeutics Announces Year End 2021 Financial Results and Provides Business UpdateMarch 3, 2022 | finance.yahoo.comPre-market Movers: MDJH, ELMS, EXC, PYPL, PHAR…February 3, 2022 | nasdaq.comEntasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.February 2, 2022 | finance.yahoo.comEntasis gains on buyout proposal from InnovivaFebruary 2, 2022 | seekingalpha.comEntasis Therapeutics Holdings Inc. Common Stock (ETTX)January 12, 2022 | nasdaq.comEntasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022January 10, 2022 | finance.yahoo.comIs Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Deliver On Growth Plans?November 12, 2021 | nasdaq.comHow Many Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Shares Do Institutions Own?November 12, 2021 | finance.yahoo.comEntasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business UpdateNovember 4, 2021 | finance.yahoo.comEntasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021October 28, 2021 | finance.yahoo.comEntasis' (ETTX) Phase III Study on Infection Drug Meets GoalOctober 20, 2021 | finance.yahoo.comEntasis Shares Rally On Positive Data From Drug-Resistant Bacterial Infection CandidateOctober 19, 2021 | finance.yahoo.comZai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK TrialOctober 19, 2021 | finance.yahoo.comEntasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR)October 19, 2021 | apnews.comBRIEF-Entasis Therapeutics Announces Positive Topline Results For Sulbactam-Durlobactam From Phase 3 Attack TrialOctober 19, 2021 | msn.comEntasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trialOctober 18, 2021 | finance.yahoo.comEntasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare ConferenceSeptember 23, 2021 | finance.yahoo.comEntasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare ConferenceSeptember 23, 2021 | benzinga.comModerna Highlights New Clinical Data on its COVID-19 VaccineSeptember 17, 2021 | nz.finance.yahoo.comWhy Are Entasis Therapeutics Shares Moving Higher On Thursday?September 16, 2021 | msn.comProfile of Entasis Therapeutics ETX0462 Candidate Published in the Journal NatureSeptember 15, 2021 | finance.yahoo.com Get Entasis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here ETTX Media Mentions By Week ETTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ETTX News Sentiment▼0.000.41▲Average Medical News Sentiment ETTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ETTX Articles This Week▼00▲ETTX Articles Average Week Get Entasis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Theravance Biopharma News Today GH Research News Today Organogenesis News Today Cartesian Therapeutics News Today Amylyx Pharmaceuticals News Today XOMA News Today YS Biopharma News Today Cryoport News Today Zevra Therapeutics News Today Foghorn Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ETTX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entasis Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entasis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
